Royal Boskalis Westminster N.V.

ENXTAM:BOKA Stock Report

Market Cap: €4.3b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Royal Boskalis Westminster Balance Sheet Health

Financial Health criteria checks 4/6

Key information

16.2%

Debt to equity ratio

€404.60m

Debt

Interest coverage ratio12.8x
Cash€537.50m
Equity€2.49b
Total liabilities€2.60b
Total assets€5.09b

Recent financial health updates

Royal Boskalis Westminster (AMS:BOKA) Has A Pretty Healthy Balance Sheet

Oct 18
Royal Boskalis Westminster (AMS:BOKA) Has A Pretty Healthy Balance Sheet

Is Royal Boskalis Westminster (AMS:BOKA) A Risky Investment?

May 27
Is Royal Boskalis Westminster (AMS:BOKA) A Risky Investment?

Recent updates

Is Royal Boskalis Westminster N.V. (AMS:BOKA) Potentially Undervalued?

Feb 24
Is Royal Boskalis Westminster N.V. (AMS:BOKA) Potentially Undervalued?

Is It Time To Consider Buying Royal Boskalis Westminster N.V. (AMS:BOKA)?

Nov 25
Is It Time To Consider Buying Royal Boskalis Westminster N.V. (AMS:BOKA)?

Royal Boskalis Westminster (AMS:BOKA) Has A Pretty Healthy Balance Sheet

Oct 18
Royal Boskalis Westminster (AMS:BOKA) Has A Pretty Healthy Balance Sheet

Why Royal Boskalis Westminster N.V. (AMS:BOKA) Could Be Worth Watching

Aug 21
Why Royal Boskalis Westminster N.V. (AMS:BOKA) Could Be Worth Watching

Investors Could Be Concerned With Royal Boskalis Westminster's (AMS:BOKA) Returns On Capital

Jul 29
Investors Could Be Concerned With Royal Boskalis Westminster's (AMS:BOKA) Returns On Capital

A Look At The Intrinsic Value Of Royal Boskalis Westminster N.V. (AMS:BOKA)

Jul 08
A Look At The Intrinsic Value Of Royal Boskalis Westminster N.V. (AMS:BOKA)

Is Royal Boskalis Westminster (AMS:BOKA) A Risky Investment?

May 27
Is Royal Boskalis Westminster (AMS:BOKA) A Risky Investment?

Increases to CEO Compensation Might Be Put On Hold For Now at Royal Boskalis Westminster N.V. (AMS:BOKA)

May 05
Increases to CEO Compensation Might Be Put On Hold For Now at Royal Boskalis Westminster N.V. (AMS:BOKA)

Investors Could Be Concerned With Royal Boskalis Westminster's (AMS:BOKA) Returns On Capital

Apr 28
Investors Could Be Concerned With Royal Boskalis Westminster's (AMS:BOKA) Returns On Capital

Are Investors Undervaluing Royal Boskalis Westminster N.V. (AMS:BOKA) By 35%?

Mar 25
Are Investors Undervaluing Royal Boskalis Westminster N.V. (AMS:BOKA) By 35%?

Royal Boskalis Westminster N.V. (AMS:BOKA) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 09
Royal Boskalis Westminster N.V. (AMS:BOKA) Just Reported And Analysts Have Been Lifting Their Price Targets

Investors In Royal Boskalis Westminster N.V. (AMS:BOKA) Should Consider This, First

Mar 07
Investors In Royal Boskalis Westminster N.V. (AMS:BOKA) Should Consider This, First

How Many Royal Boskalis Westminster N.V. (AMS:BOKA) Shares Do Institutions Own?

Feb 15
How Many Royal Boskalis Westminster N.V. (AMS:BOKA) Shares Do Institutions Own?

Is Royal Boskalis Westminster (AMS:BOKA) Using Capital Effectively?

Jan 18
Is Royal Boskalis Westminster (AMS:BOKA) Using Capital Effectively?

Royal Boskalis Westminster's (AMS:BOKA) Stock Price Has Reduced 48% In The Past Five Years

Dec 14
Royal Boskalis Westminster's (AMS:BOKA) Stock Price Has Reduced 48% In The Past Five Years

Our Take On Royal Boskalis Westminster's (AMS:BOKA) CEO Salary

Nov 24
Our Take On Royal Boskalis Westminster's (AMS:BOKA) CEO Salary

Financial Position Analysis

Short Term Liabilities: BOKA's short term assets (€1.8B) do not cover its short term liabilities (€2.0B).

Long Term Liabilities: BOKA's short term assets (€1.8B) exceed its long term liabilities (€596.3M).


Debt to Equity History and Analysis

Debt Level: BOKA has more cash than its total debt.

Reducing Debt: BOKA's debt to equity ratio has increased from 9.3% to 16.2% over the past 5 years.

Debt Coverage: BOKA's debt is well covered by operating cash flow (92.7%).

Interest Coverage: BOKA's interest payments on its debt are well covered by EBIT (12.8x coverage).


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/09/20 07:20
End of Day Share Price 2022/09/20 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Royal Boskalis Westminster N.V. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert Jan VosABN AMRO Bank N.V.
Christoph GreulichBerenberg
David VagmanBNP Paribas Exane